TITLE

Choosing the Right Weight Loss Medication for Your Patient Requires Careful Consideration

AUTHOR(S)
Still, Christopher
PUB. DATE
December 2015
SOURCE
Bariatric Times;Dec2015, Vol. 12 Issue 12, p3
SOURCE TYPE
Periodical
DOC. TYPE
Editorial
ABSTRACT
The author discusses how to match a patient with the right weight loss medication given his risk, medical history and preferences. He cites the 5 Food and Drug Administration (FDA) approved pharmacotherapy options for treating obesity including phentermine, orlistat and phentermine/topiramate extended release. He points to the other factors when choosing medication that a provider should carefully consider such as drug factors, patient factors and physician factors.
ACCESSION #
111942087

 

Related Articles

  • A pharmacologic approach to obesity. Lucas, Charles P.; Segal, Karen R.; Hauptman, Jonathan // Contemporary OB/GYN;Jun2000, Vol. 45 Issue 6, p18 

    Evaluates the effectiveness of orlistat for the treatment of obesity. Gender-specific effects of obesity; Effect of orlistat on weight loss; Side effects of orlistat. INSET: Fighting obesity.

  • The skinny on errors with obesity drug names.  // Pharmacy Today;May2015, Vol. 21 Issue 5, p88 

    The article offers information on medications related to or used in the treatment of obesity. Topics discussed include potential confusion between the trade names Xeloda, an anticancer medication, and Xenical, an antiobesity drug, rules created by a hospital unto its computer system to alert...

  • Evaluation of Safety and Anti-obese Activity of a Polyherbal Formulation -- Simlim Capsule. Shah, Bijal N.; Soni, Hardik K.; Patel, Ghanshyam R.; Patel, Pooja D.; Paranjape, Archana N. // International Journal of Pharmaceutical & Phytopharmacological R; 

    Obesity is one the most common and now considered as global health problem which triggers many other metabolic disorders. In the present study, a polyherbal formulation - Simlim Capsule was evaluated for its anti-obesity activity in high fat diet (HFD) induced male Wistar albino rats. It was...

  • Pharmacotherapy for obesity in menopausal women. Samat, Ashish; Rahim, Asad; Barnett, Anthony // Menopause International;Jun2008, Vol. 14 Issue 2, p57 

    Weight gain, during and after the menopause is common. Contributing factors include ethnicity, reduced physical activity, reduced lean mass, reduced resting metabolic rate and treatment with certain drugs, e.g. steroids, insulin, glitazones. Excess body weight increases the risk of medical...

  • New Trends in Medicinal Chemistry Approaches to Antiobesity Therapy. Jinhwa Lee; Kwang-Seop Song; Jahyo Kang; Suk Ho Lee; Junwon Lee // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p564 

    The prevalences of overweightedness and obesity are increasing globally at frightening rates, driven by social and economic changes. Furthermore, obesity is associated with the pathogeneses of major diseases, particularly diabetes and cardiovascular diseases. However, no satisfactorily safe,...

  • Anti-obesity drug use before professional treatment in Taiwan. Tsan-Hon Liou; Chih-Hsing Wu; Hsu-Chen Chien; Wen-Yuan Lin; Wei-Jei Lee; Pesus Chou // Asia Pacific Journal of Clinical Nutrition;Sep2007, Vol. 16 Issue 3, p580 

    Between July 2004 and June 2005, a cross-sectional study was performed to determine the prevalence and patterns of anti-obesity medicine use among subjects seeking obesity treatment in Taiwan. Eighteen obesity outpatient clinics were selected via a random stratified sampling method and 1,060...

  • Obesity drug endorsed by NICE. Wise, Jacqui // BMJ: British Medical Journal (International Edition);03/17/2001, Vol. 322 Issue 7287, p637 

    Reports on the possible availability of the anti-obesity drug orlistat (Xenical) throughout England and Wales on the National Health Service. Decision made by the National Institute for Clinical Excellence (NICE); Guidelines for prescribing orlistat, as one part of the management of obesity;...

  • WEIGHT WATCHER. Springen, Karen // Newsweek;2/6/2006, Vol. 147 Issue 6, p70 

    This article discusses the pros and cons of taking the weight loss drug orlistat, a medication which is marketed by Roche and is sold under the name of Xenical. Orlistat is prescribed by doctors as a weight loss drug and is typically recommended only for those patients suffering from...

  • SECTION 7 METABOLIC DISORDERS.  // MPR - Pharmacist's Edition;Fall2014, Vol. 8 Issue 3, p131 

    The article offers information on several drugs for the treatment of obesity. The Belviq weight-loss medication from pharmaceutical firm Eisai Co. Ltd. should be used together with a reduced-calorie diet and weight maintenance to treat obesity. Obese patients are advised to take the Qsymia...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics